Compound ID | 49
SASPject4
Class: Bacteriophage and/or bacteriophage-derived product
| Agent Type: | Bacteriophage or bacteriphage-derived product; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Utilises small acid soluble spore proteins which bind to DNA |
| Target Pathogen: | Active against Escherichia coli an d Klebsiella pneumoniae |
| Propensity to select resistant mutants: | Yes |
| Description: | Developed for systemic/intravenous application; delivered by bacteriophage |
| Institute where first reported: | Phico Therapeutics Ltd., UK |
| Year first mentioned: | 2014 |
| Highest developmental phase: | Preclinical |
| Development status: | Experimental |
| External links: | |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.